Another one? [GxP / QC / QA]

posted by Ajay Gupta – India, 2023-07-24 06:19 (662 d 16:24 ago) – Posting: # 23685
Views: 10,935

Dear Sir,
This is wrt synapse CRO issue Article 31 is triggered by AEMPS, procedure being already started, impacting authorised MAA and ongoing procedures using Synapse BE study. We would like to know ur expert opinion on the MHRA authorisations in case of the negative outcome of this procedure (revocations/ suspensions of MAA), or how it was handled by MHRA in similar case of Synchron BE studies and EU suspended all the related product! May I request your kind advice wrt impact on UK licenses in this scenario ! Thank you!

Regards,
Ajay Gupta

Edit: Full quote removed. Please delete everything from the text of the original poster which is not necessary in understanding your answer; see also this post #5! [Ohlbe]
wrt ur… The forum is not SMS, WhatsApp, Telegram, Signal, Threema. Please take your time and use words.
See also there. [Helmut]

Complete thread:

UA Flag
Activity
 Admin contact
23,424 posts in 4,927 threads, 1,671 registered users;
159 visitors (0 registered, 159 guests [including 32 identified bots]).
Forum time: 22:43 CEST (Europe/Vienna)

A statistical analysis, properly conducted, is a delicate dissection of
uncertainties, a surgery of suppositions.    Micheal J. Moroney

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5